Welcome to the FEMTOBIOMED Blog!

The CellShot Badger Development Story

Since COVID-19, the limitless potential of mRNA in the development of innovative therapeutics has been demonstrated, leading to an explosive increase in research on non-viral cell therapy. While LNP technology has been successful in effectively protecting and delivering mRNA into cells, the potential of technologies that do not require delivery media like LNP or Lipofectamine, such as EP (electroporation), has become increasingly apparent for the development of broad-scale cell therapy. However, because mRNA, which is easily destroyed, cannot be mixed with cell solutions, delivery has traditionally been achieved by mixing mRNA with an appropriate EP buffer, which is low in cytotoxicity and RNase-free. While this mixed delivery method is effective for research-oriented intracellular delivery, the cytotoxicity of the EP buffer and the low yield caused by cell damage and loss during the cell washing process make it difficult to apply to commercial cell manufacturing processes. In particular, autologous cells collected from patients have a very limited number of applicable cells, and many of them are difficult to expand and culture. Therefore, it is crucial to avoid the use of EP buffer, a key factor that significantly hinders process yield.